Funds and ETFs Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-05-17 pm EDT 5-day change 1st Jan Change
982.3 USD +1.48% Intraday chart for Regeneron Pharmaceuticals, Inc. +0.87% +11.84%

ETFs positioned on Regeneron Pharmaceuticals, Inc.

Name Weight AuM 1st Jan change Investor Rating
0.22% 34 M€ +12.66% -
0.21% 57 M€ +22.09% -
0.20% 1,006 M€ -.--% -
0.20% 414 M€ +13.07% -
0.19% 7 M€ +6.72% -
0.19% 32 M€ +2.00% -
0.19% 17 M€ +6.71% -
0.19% 4 M€ -.--% -
0.19% 29 M€ -.--% -
0.19% 322 M€ +13.88% -
0.17% 2,517 M€ +13.31% -
0.17% 284 M€ -.--%
0.16% 1,166 M€ +0.26% -
0.16% 607 M€ +0.05% -
0.16% 14 M€ +16.19% -
0.16% 23 M€ -.--% -
0.16% 786 M€ -.--%
0.15% 206 M€ -.--%
0.14% 571 M€ +8.53% -
0.13% 283 M€ +21.02%
0.13% 0 M€ 0.00% -
0.12% 15 M€ -1.62% -
0.11% 34 M€ +9.12% -
0.11% 391 M€ +9.52% -
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from product sales (56.6%); - revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%); - other (3%): primarily revenues from sales of technology licenses and subcontracted research services. At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
27
Last Close Price
982.3 USD
Average target price
1,042 USD
Spread / Average Target
+6.03%
Consensus
  1. Stock Market
  2. Equities
  3. REGN Stock
  4. Funds and ETFs Regeneron Pharmaceuticals, Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW